The use of PSA testing by urologists and primary care physiciansis much lower than that suggested by practitioner- and patient-based publishedself-report estimates, according to a study of national clinic-report dataconducted by urologists at the University of Michigan, Ann Arbor.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.